What are your top takeaways from SABCS 2023?
3
4 Answers
Mednet Member
Radiation Oncology · The University of Texas MD Anderson Cancer Center
- The B51 trial surprised the radiation oncology community, showing that in patients with an exceptional response to systemic therapy, radiation to the regional nodes did not result in a significant improvement in the invasive breast cancer recurrence free interval nor the isolated loco-regional recu...
Mednet Member
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida
- INAVO120 study: The study looked at triplet therapy using inavolisib (PIK3CA inhibitor) plus palbociclib and fulvestrant vs. palbociclib and fulvestrant in women with metastatic ER+HER2- breast cancer that has recurred while on or within 12 months of adjuvant endocrine therapy. The progression free...
Mednet Member
Medical Oncology · Washington University School of Medicine
- GS03-13: Phase III study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: INAVO120 primary analysis. The progression free survival improvement from adding i...
Mednet Member
Medical Oncology · Ohio State University
- Updated analysis of the KATHERINE trial at a median follow up of 8.4 years that continues to show clinically and statistically significant benefits of adjuvant TDM1 as compared to trastuzumab in women with HER2-positive breast cancer who have residual disease after neo-adjuvant chemotherapy. The up...